Results 171 to 180 of about 16,087 (221)

Ventricular arrhythmogenesis in pulmonary hypertension: From right ventricular remodeling to clinical implications

Physiological Reports, Volume 14, Issue 16, August 2026.
Abstract Pulmonary hypertension (PH) results in chronic pressure overload of the right ventricle, leading to progressive structural, metabolic, neurohumoral, and electrophysiological remodeling. Although right ventricular failure is the major determinant of outcomes in PH, these remodeling processes may also create a substrate for ventricular ...
Abdulkadir Kiris, Peng Zhang, Peter Bronk, Bum‐Rak Choi, Gaurav Choudhary   +4 more
wiley   +1 more source

Correction: Dapagliflozin attenuates hypoxia/reoxygenation-caused cardiac dysfunction and oxidative damage through modulation of AMPK. [PDF]

Cell Biosci
Tsai KL, Hsieh PL, Chou WC, Cheng HC, Huang YT, Chan SH.   +5 more
europepmc   +1 more source

SGLT2 Inhibition Attenuates Renal Tubular Senescence by Suppressing CTRP1‐Mediated Glucotoxic Stress in Diabetic Kidney Disease

The FASEB Journal, Volume 40, Issue 14, 31 July 2026.
Hyperglycemia upregulates CTRP1 and SGLT2 in renal tubular cells, promoting glucose influx, CTRP1‐mediated glucotoxic stress, and tubular senescence in diabetic kidney disease. In the experimental model, SGLT2 inhibition with dapagliflozin was associated with reduced glucose uptake, attenuation of tubular senescence, suppression of CTRP1‐related ...
Lina Gu, Buhui Liu, Lei Zhang, Jing Zhao, Weiming He, Hong Lang, Wei Sun   +6 more
wiley   +1 more source

Diabetes and hyperglucosuria exacerbate the severity of urinary tract infection caused by uropathogenic <i>E</i>. <i>coli</i> in the mouse model. [PDF]

Infect Immun
Neupane S, George I, Vanitshavit V, Hejtmancik T, Kim DM, Wright G, Adams LG, Subashchandrabose S.   +7 more
europepmc   +1 more source

Dapagliflozin-Based Therapies in Patients With Type 2 Diabetes Mellitus in an Outpatient Real-World Setting Across India: The DAPATURN Study. [PDF]

Cureus
Chawla R, T K S, Singh KP, Mehta A, Chattopadhyay M, Rakshit KM, Motiramani N, Philip R, Shinde AC, K SM, Revenkar S, Patel K.   +11 more
europepmc   +1 more source

Cardiorenal Outcomes of Dapagliflozin vs. Empagliflozin in Advanced Chronic Kidney Disease and Diabetes. [PDF]

Clin Pharmacol Ther
Lin SH, Chen JJ, Hsiao CC, Fang YW, Chen MT, Tsai MH, Yang HY.   +6 more
europepmc   +1 more source

Comparison of effectiveness and safety of bexagliflozin and other sodium-glucose cotransporter 2 inhibitors for type 2 diabetes mellitus in adults: systematic review and network meta-analysis of randomized controlled trials. [PDF]

Front Endocrinol (Lausanne)
Gao S, Zhang F, Xie X, Fan L.
europepmc   +1 more source

Comparative Effectiveness of Individual Sodium Glucose Transporter 2 Inhibitors on Cardiovascular Outcomes in Type 2 Diabetes With Moderate Cardiovascular Risk: Emulation of a Target Trial. [PDF]

J Am Heart Assoc
Zehra A, Deng Y, Swarna KS, Herrin J, Polley EC, Neumiller JJ, Galindo RJ, Umpierrez GE, Ross JS, Brito JP, Montori VM, Borah BJ, Maron BA, Mickelson MM, McCoy RG.   +14 more
europepmc   +1 more source

Correspondence: Effects of short‐term tofogliflozin treatment on insulin secretory capacity in type 2 diabetes: Insights and future directions

Journal of Diabetes Investigation, Volume 17, Issue 8, Page 1440-1441, August 2026.
Gargi Bisht, Nitin Kumar Indora
wiley   +1 more source

Reassessing the risk-modifying effects of novel antidiabetic agents on asthma-COPD overlap syndrome: a dose-stratified network meta-analysis of 316,832 adults from 128 randomised trials. [PDF]

EClinicalMedicine
Zeng BY, Hsu CW, Hung CM, Yang WC, Stubbs B, Chen YW, Lei WT, Chen JJ, Chen TY, Hsu SP, Wang HY, Shiue YL, Zeng BS, Li CT, Su KP, Liang CS, Suen MW, Tseng PT.   +17 more
europepmc   +1 more source